- Datum02.04.2025
- Uhrzeit15:00 - 16:00 Uhr
- Veranstalter
XTB
Jochen Schmidt
Moderator
Corbus Pharmaceuticals Holdings Aktie
Verkaufen
Kaufen
Corbus Pharmaceuticals Holdings Chart
Corbus Pharmaceuticals Holdings Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-5,27 %
Intraday
-15,03 %
1 Woche
-33,38 %
1 Monat
-57,37 %
Seit Jahresbeginn
-86,57 %
1 Jahr
-68,56 %
3 Jahre
-96,57 %
5 Jahre
Wikifolio
Passender Service zu Corbus Pharmaceuticals Holdings
Webinar zu Corbus Pharmaceuticals Holdings
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,915-61,900
- Jahrestief / Hoch ($)4,915-13,280
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Corbus Pharmaceuticals Holdings
Keine Dividenden verfügbar
Termine von Corbus Pharmaceuticals Holdings
Keine aktuellen Termine
Beschreibung
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
